We have collected information about Antibody-Drug Conjugates Targeted Drug Delivery For Cancer for you. Follow the links to find out details on Antibody-Drug Conjugates Targeted Drug Delivery For Cancer.
https://www.sciencedirect.com/science/article/pii/S136759311000075X
Antibody–drug conjugates (ADCs) represent one approach, where the ability to harness mAb specificity and target the delivery of a cytotoxic agent to the tumor may significantly enhance both mAb and drug activities.Author: Stephen C Alley, Nicole M Okeley, Peter D Senter
https://www.ncbi.nlm.nih.gov/pubmed/20643572
The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technology, and the stoichiometry and placement of conjugated drugs.Author: Stephen C Alley, Nicole M Okeley, Peter D Senter
https://www.sciencedirect.com/science/article/abs/pii/S136759311000075X
Antibody–drug conjugates: targeted drug delivery for cancer. The antibody–drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technology, and the stoichiometry and placement of …Author: Stephen C Alley, Nicole M Okeley, Peter D Senter
https://www.researchgate.net/publication/45274741_Antibody-drug_conjugates_Targeted_drug_delivery_for_cancer
Antibody-drug conjugates: Targeted drug delivery for cancer. The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technology, and the stoichiometry and placement of …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508879/
Antibody drug conjugates (ADCs) Parallel to the development of TMAs has been the emergence of ADCs. ADCs bring together the targeting advantages of antibodies with the cytotoxic potential of chemotherapy, heralding the promise of targeted accumulation of drug in the tumor tissue.Author: Michael A Firer, Gary Gellerman
https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-70
Nov 09, 2012 · In parallel to naked TMAs, antibody-drug conjugates (ADCs) have been developed for targeted delivery of potent anti-cancer drugs with the aim of bypassing the morbidity common to conventional chemotherapy.Author: Michael A Firer, Gary Gellerman
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634700/
Although it has taken more than a century to translate Ehrlich’s dream of “magic bullet” into therapeutic reality, with the documented clinical success of antibody-drug conjugates, Adcetris and Kadcyla, perhaps these “drug bullets” targeted to cancer cells may turn out to be truly “magical” and eventually lead to a cure for patients with lymphoma and breast cancers.Author: Rodney J. Y. Ho, Jenny Chien
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769513/
Sep 03, 2019 · These include antibody-drug conjugates (ADCs) [29,30,31], radioimmunoconjugates (RICs) [32,33], small molecule-drug conjugates (SMDCs) , and drug conjugates to tumor-targeting peptides and synthetic polymers (PDCs) [35,36]. Such conjugate-based drug delivery systems share commonalities with respect to their functional construction, comprising a tumor recognition moiety and …Author: Alexander Y. Deneka, Yanis Boumber, Tim Beck, Erica A. Golemis
https://www.sciencedirect.com/science/article/pii/S0169409X01002277
Targeted drug conjugates appear to be limited by the lack of cytotoxicity of many of the common anti-cancer drugs available for conjugation. Antibody concentration is an important determinant of the rate of drug uptake; therefore, if more drug molecules can be …Author: Martin C Garnett
Searching for Antibody-Drug Conjugates Targeted Drug Delivery For Cancer?
You can just click the links above. The data is collected for you.
